Alpha Diagnostic International's (ADI) Mouse ZIKV Env ELISA kits were used in the peer reviewed paper published yesterday in the journal Nature. The authors demonstrate that two different ZIKV vaccine candidates provided complete protection in mice against a ZIKV strain from Brazil and suggest that a ZIKV vaccine for humans will likely be feasible. The rapid development of a safe and effective vaccine to prevent the Zika virus (ZIKV) is a global priority, as infection in pregnant women has been shown to lead to fetal microcephaly and other major birth defects. Science Daily news release reported that vaccine protection against Zika has been achieved- https://www.sciencedaily.com/releases/2016/06/160628114836.htm
The neutralizing antibodies that provided immunity to Zika infection were assessed using ADI’s ZIKV Env ELISA kits. http://www.nature.com/nature/journal/vaap/ncurrent/pdf/nature18952.pdf
ADI's mission is to develop and supply diagnostic and validating solutions for promoting global health through improved vaccine therapeutics and mitigating the spread of human and animal diseases.
ADI has remained faithful to its mission by being the first company to develop ELISA kits during the Ebola virus epidemic in Africa as well as the Zika virus episodes in Brazil and the Americas. ADI has developed multiple Zika virus antibody (IgM and IgG) ELISA kits for humans, mice and monkeys which are currently being used for zika virus detection and vaccine development. It is worth recalling that ZIKV is a member of the flavivirus family of viruses which are transmitted by mosquitoes, and ZIKV is responsible for an unprecedented epidemic in the Americas.
Please visit the link for ADI Zika products which include ELISA kits, antibodies and recombinant proteins-
ADI supports research, diagnostic and vaccine development for diseases diagnostics, surveillance and prevention.